First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)

MLA

Rosine Guimbaud, et al. “First European Phase II Trial of Intravenous (Iv) Cetuximab (Cet) and Hepatic Artery Infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt KRAS Colorectal Cancer (CRC) after Systemic Therapy Failure (OPTILIV, NCT00852228).” Journal of Clinical Oncology, vol. 30, May 2012, p. 3547. EBSCOhost, https://doi.org/10.1200/jco.2012.30.15_suppl.3547.

APA

Rosine Guimbaud, Philippe Rougier, René Adam, Abdoulaye Karaboué, Thierry de Baere, Pasquale F. Innominato, C. N. J. Focan, Salvatore Tumolo, Denis Castaing, Francis Lévi, Carlos Carvalho, Céline Lepère, Michel Ducreux, Valérie Boige, Mohamed Bouchahda, Mohamed Hebbar, Y. Ajavon, & Laetitia Proux. (2012). First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228). Journal of Clinical Oncology, 30, 3547. https://doi.org/10.1200/jco.2012.30.15_suppl.3547

Chicago

Rosine Guimbaud, Philippe Rougier, René Adam, Abdoulaye Karaboué, Thierry de Baere, Pasquale F. Innominato, C. N. J. Focan, et al. 2012. “First European Phase II Trial of Intravenous (Iv) Cetuximab (Cet) and Hepatic Artery Infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt KRAS Colorectal Cancer (CRC) after Systemic Therapy Failure (OPTILIV, NCT00852228).” Journal of Clinical Oncology 30 (May): 3547. doi:10.1200/jco.2012.30.15_suppl.3547.